This site provides INTERCEPT product information for International audiences Select your region
Transfusion-Associated Bacterial Sepsis Becomes History
No cases of bacterial sepsis or fatalities have been reported since the introduction of the INTERCEPT™ Blood System for platelets (2005 in France, and 2009 in Switzerland), as demonstrated by French, Swiss and Belgium national haemovigilance data. The French, Swiss and Belgium authorities also reported these numbers on bacterial sepsis and fatalities, specific to conventional untreated platelets:
- From 2009 to 2014, the French national haemovigilance programme reported 46 cases of bacterial sepsis including eight fatalities caused by bacterial-contaminated platelet concentrates in the regions that had not yet adopted the INTERCEPT Blood System.
- From 2005 to 2011, the Swiss national haemovigilance programme reported 16 septic transfusion reactions caused by bacterial-contaminated platelet concentrates, including three deaths.
‘Since the pathogen inactivation (PI) process has been implemented for all platelet concentrates (PC) in Switzerland, no additional cases of sepsis due to PC have been reported’.
Swissmedic Annual Haemovigilance Report, 2014